News Noom expands its GLP-1 range with 'microdose' package Noom is offering 'microdoses' of semaglutide at a knock-down price, claiming they can prevent side effects but remain effective for weight loss.
News Noom offers cut-price compounded GLP-1 drug for obesity Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.
News Sanofi reported to be looking at an Insmed takeover Sanofi CEO Belén Garijo has said she wants to make M&A deals, and the rumour mill is now linking the French group to a possible takeover of Insmed.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.